Study assesses first-line type 2 treatments

Type 2 diabetes patients who receive metformin as a first-line therapy are less likely to need treatment intensification than those started on other drugs, according to a US study that endorses current practice.

Using data from 15,500 patients who had been prescribed an oral medication, they found 58% received metformin as their initial treatment. Of these, 25% needed a second oral medication.

The need for secondary medication was 37% for sulfonylureas, 39% for thiazolidinedione and 36% for those prescribed a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor).